Search Results
Search for other papers by Claudia Lanari in
Google Scholar
PubMed
Search for other papers by Victoria Wargon in
Google Scholar
PubMed
Search for other papers by Paola Rojas in
Google Scholar
PubMed
Search for other papers by Alfredo A Molinolo in
Google Scholar
PubMed
Introduction Breast cancer is the most frequently diagnosed malignant neoplasia and is a leading cause of cancer death in females worldwide. Breast cancer ranks second overall in cancer mortality (10.9%) and accounts for 23% (1.38 million) of new
Search for other papers by Michael G Apps in
Google Scholar
PubMed
Search for other papers by Eugene H Y Choi in
Google Scholar
PubMed
Search for other papers by Nial J Wheate in
Google Scholar
PubMed
platinum drug ( Wheate et al . 2010 ). Platinum drugs are used to treat a wide variety of cancers, including some endocrine-related cancers: testicular and ovarian carcinomas. They are also used to treat melanoma, small-cell and non-small-cell lung cancer
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Search for other papers by Matthew J Schiewer in
Google Scholar
PubMed
Search for other papers by Robert Den in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Search for other papers by David T Hoang in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Search for other papers by Michael A Augello in
Google Scholar
PubMed
Search for other papers by Yaacov R Lawrence in
Google Scholar
PubMed
Search for other papers by Adam P Dicker in
Google Scholar
PubMed
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Kimmel Cancer Center, Cancer Biology, Urology, Radiation Oncology, Departments of
Search for other papers by Karen E Knudsen in
Google Scholar
PubMed
Introduction Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous malignancy and the second leading cause of death due to cancer in men in the United States ( Jemal et al . 2010 ). Treatment options for localized disease include
Search for other papers by Bin Zhao in
Google Scholar
PubMed
Search for other papers by Hong Zhao in
Google Scholar
PubMed
The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China
Search for other papers by Jiaxin Zhao in
Google Scholar
PubMed
Introduction Approximately 20% patients with breast cancer (BC) have HER2-positive disease. These patients are often associated with a highly aggressive tumor behavior and poor outcomes ( Slamon et al . 1987 ). Therefore, HER2 has become an
Search for other papers by T Frogne in
Google Scholar
PubMed
Search for other papers by J S Jepsen in
Google Scholar
PubMed
Search for other papers by S S Larsen in
Google Scholar
PubMed
Search for other papers by C K Fog in
Google Scholar
PubMed
Search for other papers by B L Brockdorff in
Google Scholar
PubMed
Search for other papers by A E Lykkesfeldt in
Google Scholar
PubMed
Introduction The antiestrogen tamoxifen has been first-line endocrine therapy for estrogen receptor (ER) positive breast cancer patients for more than 25 years, and several other antiestrogens and selective ER modulators (SERMs) have
Consortium for the Study of Thyroid Cancer (CECaT), Catalonia, Spain
Search for other papers by Carles Zafon in
Google Scholar
PubMed
Search for other papers by Joan Gil in
Google Scholar
PubMed
Search for other papers by Beatriz Pérez-González in
Google Scholar
PubMed
Program of Predictive and Personalized Medicine of Cancer, Germans Trias i Pujol Research Institute (PMPPC-IGTP), Barcelona, Spain
Search for other papers by Mireia Jordà in
Google Scholar
PubMed
Introduction Thyroid cancer, the most prevalent endocrine malignancy, covers the full range of phenotypes from indolent to the worst forms of human cancer. It is categorized into differentiated thyroid cancer (DTC), poorly differentiated
Search for other papers by Marjory Alana Marcello in
Google Scholar
PubMed
Search for other papers by Lucas Leite Cunha in
Google Scholar
PubMed
Search for other papers by Fernando Assis Batista in
Google Scholar
PubMed
Search for other papers by Laura Sterian Ward in
Google Scholar
PubMed
Introduction Overweight and/or obesity have been consistently related to the development and progression of different types of cancers during the last decades. An extensive review published a few years ago estimated that approximately 20% of all
Search for other papers by L Hilakivi-Clarke in
Google Scholar
PubMed
Search for other papers by C Wang in
Google Scholar
PubMed
Search for other papers by M Kalil in
Google Scholar
PubMed
Search for other papers by R Riggins in
Google Scholar
PubMed
Search for other papers by R G Pestell in
Google Scholar
PubMed
Introduction Breast cancer accounts for approximately 30% of all cancers diagnosed in women in the USA. As the second leading cause of cancer death in women, breast cancer accounts for approximately 15% of all female cancer deaths
Search for other papers by Simon Linder in
Google Scholar
PubMed
Search for other papers by Henk G van der Poel in
Google Scholar
PubMed
Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands
Search for other papers by Andries M Bergman in
Google Scholar
PubMed
Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands
Search for other papers by Wilbert Zwart in
Google Scholar
PubMed
Search for other papers by Stefan Prekovic in
Google Scholar
PubMed
Introduction Ever since the discovery that prostate cancer (PCa) growth after androgen deprivation therapy (ADT) remains dependent on androgen receptor (AR) signaling, researchers have been looking for new effective ways to block the action of
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
Search for other papers by Anastasia Alataki in
Google Scholar
PubMed
The Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK
Search for other papers by Mitch Dowsett in
Google Scholar
PubMed
Introduction Breast cancer development and progression are significantly affected by signalling pathways involving oestrogen receptor (ER) and growth factor receptors ( Arpino et al. 2008 ). Over 80% of all breast cancer cases are deemed ER